Donna Pauler Ankerst

ADDRESS: Department of Mathematics
                  Technical University Munich
                  Boltzmannstr 3
                  85748 Garching, Germany

Telephone: +49 89 289 18388
Email: ankerst@tum.de

Former Name: Donna Kay Pauler

EDUCATION

- University of Texas, Bachelor of Science in Mathematics, 1990
- Carnegie Mellon University, Master of Science in Statistics, 1994
- Carnegie Mellon University, Ph.D. in Statistics, 1996

POSITIONS

Primary Appointments

- Lecturer, University College London (UCL), London, U.K., 1996-1997
- National Science Foundation Mathematical Sciences Postdoctoral Fellow, Departments of Biostatistics and Medicine, Harvard School of Public Health, Boston, MA, 1997-2000
- Faculty Member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center Seattle, WA, Assistant 2000-2004; Associate 2004-2006
- Research Scientist, Institute for Medical Informatics, Biometry and Epidemiology, Ludwig Maximilian University (LMU), Munich, Germany, 2006-2008
- Research Professor (20% effort) , Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, Associate, 2006-2010; Full, April 1 2010-present
- Professor (100% effort), Department of Mathematics, Technical University Munich (TUM), Munich, Germany, 2008-present

Affiliate Appointments

- Affiliate Professor, Department of Biostatistics, University of Washington, Assistant 2000-2005, Associate 2005-2006
- Adjunct Associate Research Scientist, Department of Biostatistics, University of Michigan, 2006-2008
- Joint Professor Appointment, Department of Life Sciences, Technical University Munich, Weihenstephan, Germany, 2009-present

HONORS and AWARDS

- Summa cum laude, University of Texas, 1990
- Special Honors in Mathematics University of Texas, 1990
- Gertrude Cox Scholarship for top US female graduate student of the American Statistical Association, 1993
- Carnegie Mellon Scholarship for Women, full graduate tuition, 1992 to 1996
- National Science Foundation Graduate Fellowship for full research stipend, 1993 to 1996
- National Science Foundation Mathematical Sciences Postdoctoral Fellowship for full research stipend, 1997 – 2000
- Team member, "A Bavarian Dream", winner of Challenges 1b, 2 of the Prostate Dream Challenge, 2015
- PhD Supervisory Award, Graduate School Weihenstephan, 2018

FUNDED GRANTS

- Model Selection and Bayes Factors, National Science Foundation Mathematical Sciences Postdoctoral Fellowship: DMS-9627420, **DK Pauler** PI, 100% funding 1996-1999.
- Southwest Oncology Group (SWOG) Statistical Center, National Institutes of Health (NIH): U10 CA38926**,** John Crowley PI, **DK Pauler/DP Ankerst** Statistician for the Cancer Control and Correlative Outcomes Committee 2000-2005.
- SWOG Statistical Methods, NIH 5R01: CA090998, Mike LeBlanc PI, **DK Pauler/DP Ankerst** Co-investigator 2000-2005.
- PSA Based Early Detection of Prostate Cancer Recurrence, NIH R21/R33: 1 R21 CA110518-01A1, JMG Taylor, **DP Ankerst** PIs, 2005-2008.
- The San Antonio Center of Biomarkers of Risk for prostate cancer (SABOR), NIH U01 CA086402, IM Thompson PI, **DP Ankerst** Co-investigator 2000-2015.
- Improving prostate biopsy efficiency: The finasteride challenge test, NIH R01 CA138627-02, IM Thompson PI, **DP Ankerst** Co-Investigator 2010-2013.
- PROMISS-Prostate modeling to identify surveillance strategies, NIH R01, CA183570-01, R Etzioni PI, **DP Ankerst** UTHSCSA site PI 2013-2018 funded at 5%. The aim of this study is to develop prediction models and optimal screening regimes for prostate cancer patients on active surveillance.
- Dynamic, multi-cohort prediction modeling of prostate biopsy outcome, NIH R01CA179115 $2,700,000, Andrew Vickers, **DP Ankerst** PIs 2014-2019; Ankerst funded at 15%. The objective of this grant is to prospectively collect risk factors for prostate cancer and outcomes on prostate biopsy at 9 urology centers worldwide, including Puerto Rico, the Durham VA, the Cleveland Clinic Foundation, Hamburg, Germany and Milan, Italy. A family history sub-study collects detailed family history at four sites.
- SFB 824: Imaging for Selection, Monitoring and Individualization of Cancer Therapies, Speaker M. Schwaiger, Statistician DP Ankerst, 2017 – 2022, one PhD position.
- Wiklige Bayerische Verbundprojekt Klimawandel und Gesundheit, Project co-partner, 2018-2020, joint supervision of one PhD student.

TEACHING

- **University College London (for one year):** Introductory Statistics for Undergraduate Students (~80 students), Data Analysis in SPLUS for Master students (~15 students), Survey Sampling for

Diploma students (~30 students), Core Review of Statistics for non-Statistic major undergraduate students (~100 students)

- **Ludwig-Maximilians-University (for two years):** Statistical Consulting, Prognostic Factors in Clinical Epidemiology for Master of Public Health students (~25 students), Survival Analysis and Missing Data for Master of Public Health students (~25 students), Longitudinal data analyses for advanced Statistics undergraduate and diploma students (~60 students)
- **Technical University Munich (since 2008):** Introduction to Statistics for Life Science Bachelor students (800 students first two years, now annually ~50 students per section in a mixed live/online course), PhD Graduate School in Statistics (every semester, ~15 students); Applied Regression for upper level Bachelor and Master students (annually, ~100 students), Multivariate Statistics for Master students (annually, ~100 students), Computational Statistics for upper level Bachelor and Master students (bi-annually, ~150 students), Seminar in the Life Sciences for Master students (every semester with rotating topics in statistics, the R stat package, publishing, ~15 students), Consulting for Life Science PhD students (continually)
- **University of Texas Health Science Center at San Antonio:** 1 lecture on risk prediction models in 2016 + consulting to Master level statisticians from 2006 until present

BACHELOR, MASTER AND PHD THESES

- **Bachelor:** 100 to date in TUM Mathematics
- **Master:** 60 to date in TUM Mathematics, Head of the Mathematical Modeling of Biological Systems Division Master and PhD seminar program of 30 students for two years; 1 in LMU Statistics, 2 in UW Biostatistics, 2 in UCL Statistics, Head of the UCL Statistics Master program of 15 students for one year
- **PhD:** 2 in TUM Life Science Mathematics 2014, 2016; PhD committee member: 3 TUM Mathematics, 3 TUM Life Science, 3 UW Biostatistics

PROFESSIONAL SERVICE

- Referee for European Urology, Clinical Cancer Research, JASA, Journal of the Royal Statistical Society Series B (JRSSB), Statistical Science, Statistics in Medicine, Biometrics, Journal of Urology, Journal of Surgical Oncology, Biometrical Journal, Cancer Clinical Research, among others
- External review for Harvard Biostatistics Department full professor tenure, UTHSCSA Epidemiology & Biostatistics Department associate professor tenure, University of California San Diego Biostatistics associate professor tenure, University of Washington Biostatistics associate professor tenure, United Kingdom Medical Research Council Biostatistics Fellowship, Austrian Science Fund, Ireland Cancer Society grant, TUM tenure track committee for Professor of Proteomics, TUM tenure track committee for Professor of Population Genetics, TUM tenure track committee for Professor of Chemistry
- English teacher, pre-school, Bazeilles Kindergarten, Munich, Germany (2010-2011)
- Member of the American Statistical Association (ASA) and International Biometric Society (IBS) Board Member International Society of Oncological Biomarkers (ISOBM) (2007-2011), Editorial Board for Tumor Biology (2012 – 2013)
- Search committee member for W3 TUM Professor of Population Genetics, W2 TUM Professor of Population Genetics, W2 LMU Professor of Computational Statistics, W2 TUM Professor for Plant Genetics, Assistant TUM Professor Department of Vascular Biology, W2 TUM Tenure Track Professor of Risk and Insurance, W3 TUM Professor of Intelligent Extraction of Medicine
- Member, TUM Women in Mathematics Committee, 2013 to present

- Chair of the Data Safety and Monitoring Board member for the WISDOM - Women Informed to Screen Depending on Measures of Risk - study of 100,000 participants funded by the Patient-Centered Outcomes Research Institute, Principal Investigator (PI) Laura Esserman (2016 – 2020)

PEER-REVIEWED PUBLICATIONS

1. Harris IR, **Pauler DK**. Locally quadratic log likelihood and data-based transformations. Communications in Statistics Theory and Methods 21:637-646, 1992.
2. Sweeney JA, Clementz BA, Escobar MD, Li S, **Pauler DK**, Haas GL. Mixture analysis of pursuit eye tracking dysfunction in schizophrenia. Biological Psychiatry 34:331-340, 1993.
3. Arango V, Underwood MD, **Pauler DK**, Kass RE, Mann JJ. Differential loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic-suicides. Alcoholism: Clinical and Experimental Research 20:1141-7, 1996.
4. **Pauler DK**, Escobar MD, Sweeney JA, Greenhouse J. Mixture models for eye-tracking data: A Case Study. Statistics in Medicine 15:1365-1376, 1996.
5. **Pauler DK**. The Schwarz criterion and related methods for Normal linear models. Biometrika 85:13-27, 1998.
6. Laird NM, **Pauler DK**. Discussion of "Adjusting for nonignorable drop-Out using semiparametric nonresponse models'' by DO Scharfstein, A Rotnitzky and JM Robins. Journal of the American Statistical Association 94:1133-1135, 1999.
7. **Pauler DK,** Wakefield JC, Kass RE. Bayes factors for variance component models. Journal of the American Statistical Association 94:1242-1253, 1999.
8. **Pauler DK**, Laird NM. A mixture model for longitudinal data with application to assessment of noncompliance. Biometrics 56: 464-472, 2000.
9. Pinzone JJ, Katznelson L, Danila DC, **Pauler DK**, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. Journal of Clinical Endocrinology and Metabolism 85(9): 3053-7, 2000.
10. Skates SJ, **Pauler DK**, Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point models of longitudinal markers. Journal of the American Statistical Association 96:429-39, 2001.
11. **Pauler DK**, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiology, Biomarkers and Prevention 10(5): 489-93, 2001.
12. Welt CK, Smith ZA, **Pauler DK**, Hall JE. Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development. Journal of Clinical Endocrinology and Metabolism 86(6): 2531-7, 2001.
13. **Pauler DK**, Laird NM. Non-linear hierarchical models for monitoring compliance. Statistics in Medicine 21(2): 219-229, 2002.
14. **Pauler DK**, Finkelstein DM. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Statistics in Medicine 21:3897-3911, 2002.
15. **Pauler DK**, Gower KB, Goodman PJ, Crowley JJ, Thompson IM. Biomarker-based methods for determining noncompliance in a prevention trial. Controlled Clinical Trials 23:675-685, 2002.
16. **Pauler DK**, McCoy S, Moinpour C. Pattern mixture models for longitudinal quality of life studies in advanced-stage disease. Statistics in Medicine 22:795-809, 2003.

17. Ganz PA, Moinpour CM, **Pauler DK**, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI. Health status and quality of life in patients with early stage Hodgkin's disease treated on Southwest Oncology Group Study 9133, Journal of Clinical Oncology 21(18): 3512—3519, 2003.

18. Green S, **Pauler DK**. Statistics in clinical trials, Current Oncology Reports 6(1):36—41, 2004.

19. Yildiz A, **Pauler DK**, Sachs GS. Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis. Journal of Affective Disorders 78:157-162, 2004.

20. Thompson IM, **Pauler DK**, Goodman PJ, Tangen CM, Lucia SM, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. New England Journal of Medicine 350(22):2239-2246, 2004.

21. McGregor BA, Bowen DJ, **Ankerst DP,** Andersen MR, Yasui Y, McTiernan A. Optimism, perceived risk of breast cancer, and cancer worry among a community-based sample of women. Health Psychology 23(4):339-344, 2004.

22. Hansen LK, Feigl P, Modiano MR, Lopez JA, Escobedo Sluder S, Moinpour CM, **Pauler DK**, Meyskens FL. An educational program to increase cervical and breast cancer screening in Hispanic women: A Southwest Oncology Group Study, Cancer Nursing 28(1):47-53, 2005.

23. Hayden D, **Pauler DK**, Schoenfeld D. An estimator for treatment comparisons among survivors in randomized trials, Biometrics 61:305-310, 2005.

24. Thompson IM, **Ankerst DP**, Chi C, Lucia MS, Goodman P, Crowley JJ, Parnes HL, Coltman CA, Jr. The operating characteristics of prostate-specific antigen in a population with initial PSA of 3.0 ng/ml or lower, Journal of the American Medical Association 294:66--70, 2005.

25. Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang JC, Summers A, Clay TM, Morse MA, Lyerly HK, DeLaRosa C, **Ankerst DP**, Disis ML. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunology 6(1):17, doi:10.1186/1471-2172-6-17, 2005.

26. Etzioni RD, Howlader N, Shaw PA, **Ankerst DP**, Penson DF, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: Results from the Prostate Cancer Prevention Trial. Journal of Urology 174(3):877—881, 2005.

27. **Ankerst DP**, Engel J. Status of quality of life in breast cancer research before, during and beyond treatment. Expert Review of Pharmacoeconomics & Outcomes Research 6: 207-214, 2006.

28. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, **Ankerst DP**, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108: 685-696, 2006.

29. Thompson IM, **Ankerst DP**, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial, Journal of the National Cancer Institute 98: 529-534, 2006. Creator: The Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) Version 1.0.

30. Petrylak DP, **Ankerst DP**, Jiang CS, Tangen CM, Hussain MHA, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Kohli M, Bensen MC, Small EJ, Raghavan D, Crawford ED.

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16, Journal of the National Cancer Institute 98: 516-521, 2006.

31. Yildiz-Yesiloglu A, **Ankerst DP**. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30: 969-95, 2006.

32. Berry DL, Moinpour CM, Jiang CS, **Ankerst DP**, Petrylak DP, Vinson LV, Lara PN, Lanier S, Taplin ME, Burch PA, Hussain MHA, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone, Journal of Clinical Oncology 24:2828-35, 2006.

33. Yildiz-Yesiloglu A, **Ankerst DP**. Review of the (1) H magnetic resonance spectroscopy findings in major depressive disorder: A meta-analysis. Psychiatry Research 147: 1-25, 2006.

34. Baillargeon J, Platz EA, Rose DP, Pollock BH, **Ankerst DP**, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Thompson IM. Obesity, adipokines and prostate cancer in a prospective population-based study. Cancer Epidemiology, Biomarkers and Prevention 15: 1331-5, 2006.

35. Thompson IM, Chi C, **Ankerst DP**, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute 98: 1128-33, 2006.

36. Parekh DJ, **Ankerst DP**, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 68: 1152-5, 2006.

37. **Ankerst DP**, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Archivio Italiano di Urologia e Andrologia 78: 125-129, 2006.

38. **Ankerst DP**, Thompson IM. Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool. Archivio Italiano di Urologia e Andrologia 78: 143-146, 2006.

39. **Ankerst DP**, Thompson IM. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Archivio Italiano di Urologia e Andrologia 78: 154-156, 2006.

40. Markland AD, Thompson IM, **Ankerst DP**, Higgins B, Kraus SR. Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic White, Mexican American, and African American men. Urology 69: 697-702, 2007.

41. Thompson IM, **Ankerst DP**. Prostate-specific antigen in the early detection of prostate cancer. Canadian Medical Association Journal 176: 1853-8, 2007.

42. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, **Ankerst DP**, Patrick DL, Ware JE, Ganz PA, Shumaker SA, Lippman SM, Coltman CA Jr. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 99: 1025-35, 2007.

43. Fliser D, Kolleritis B, Neyer U, **Ankerst DP**, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. Journal of the American Society of Nephrology 18: 2600-8, 2007.

44. Thompson IM, **Ankerst DP**, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA, Jr. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. Journal of Clinical Oncology 25: 3076-81, 2007.

45. Bowen DJ, Fann JR, Anderson MR, Rhew IC, Gralow JR, Lewis FM, Hunt JR, Palomares M, Moinpour CM, **Ankerst DP**. Recruiting patients with breast cancer and their families to behavioral research in the post-HIPAA period. Oncology Nursing Forum 34:1049-54, 2007.

46. Parekh DP, **Ankerst DP**, Baillargeon J, Higgins B, Platz EA, Troyer D, Hernandez J, Leach RJ, Lokshin A, Thompson IM. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer, Epidemiology, Biomarkers and Prevention 16: 1966-72, 2007.

47. Reed A, **Ankerst DP**, Pollock BH, Thompson IM, Parekh DJ. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. Journal of Urology 178:1929-32, 2007.

48. Etzioni RD, **Ankerst DP**, Weiss NS, Inoue LY, Thompson IM. Is PSA velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. Journal of the National Cancer Institute 99: 1510-5, 2007.

49. Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, **Ankerst DP**, Thompson IM, Leach RJ, Parekh DJ. Prostate cancer risk with positive family history, normal prostate examination findings and PSA less than 4.0 ng/mL. Urology 70:748-52, 2007.

50. Parekh DJ, **Ankerst DP**, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. Journal of Urology 178:2252-59, 2007.

51. Boeck S, **Ankerst DP**, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology 72: 314-21, 2007.

52. Heid IM, Vollmert C, Kronenberg F, Huth C, **Ankerst DP**, Luchner A, Hinney A, Broenner G, Wichmann HE, Illig T, Doering A, Hebebrand J. Association of the MC4R V103l polymorphism with the metabolic syndrome: the KORA study. Obesity 16: 369-76, 2008.

53. Yildiz A, Guleryuz S, **Ankerst DP**, Ongur D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry 65(3):255-63, 2008.

54. Rhodes EC, Johnson-Pais TL, Singer FR, **Ankerst DP**, Bruder JM, Wisdom J, Hoon DSB, Lin E, Bone HG, Simcic KJ, Leach RJ. Sequestosome1 (SQSTM1) mutations in Paget's disease of bone from the United States. Calcified Tissue International 82(4):271-7, 2008.

55. Reed AB, **Ankerst DP**, Leach RJ, Vipraio G, Thompson IM, Parekh DJ. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C. Journal of Urology 180(2):534-7, 2008.

56. Thompson IM, Tangen CM, **Ankerst DP,** Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA, Jr. The performance of PSA for predicting prostate cancer is maintained after a prior negative prostate biopsy. Journal of Urology 180(2):544-7, 2008.

57. Miyamoto RK, Chabi A, Johnson DA, **Ankerst DP**, Thompson IM, Rozanski TA. Complicated cataract surgery in patients receiving alpha blockers for benign prostatic hyperplasia. UroToday International Journal 1: doi:10.3834/uij.1939-4810.2008.07.05, 2008.

58. **Ankerst DP,** Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. Journal of Urology 180(4): 1303-8, 2008.

59. Thompson IM, **Ankerst DP**, Etzioni R, Wang T. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. <u>Journal of Urology</u> 180(4): 1219-22, 2008.

60. Blankenburg F, Hatz R, Nagel D, **Ankerst D**, Reinmiedl J, Gruber C, Seidel D, Stieber P. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. External validation of a prognostic score. <u>Tumor Biology</u> 29(4): 272-77, 2008.

61. Parekh AD, Thomas JC, Trusler L, **Ankerst DP**, Deshpande JK, Adams MC, Pope JC 4th, Brock JW 3rd. Prospective evaluation of health related quality of life for pediatric patients with ureteropelvic junction obstruction. <u>Journal of Urology</u> 180(5): 2171-5, 2008.

62. Taylor JMG, **Ankerst DP**, Andridge RR. Validation of biomarker-based risk prediction models. <u>Clinical Cancer Research</u> 14(19): 5977-83, 2008.

63. Proust-Lima C, Taylor JM, Williams SG, **Ankerst DP**, Liu N, Kestin LL, Bae K, Sandler HM. Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. <u>International Journal of Radiation Oncology, Biology, Physics</u> 72(3): 782-91, 2008.

64. Shepherd BE, Redman MW, **Ankerst DP**. Does finasteride affect the severity of prostate cancer? A causal sensitivity analysis. <u>Journal of the American Statistical Association</u> 103(484): 1392-1404, 2008.

65. Jansson AF, Mueller TH, Gliera L, **Ankerst DP**, Wintergerst U, Belohradsky BH, Jansson V. Clinical score for non-bacterial osteitis in children and adults. <u>Arthritis & Rheumatism</u> 60(4): 1152-59, 2009.

66. Dieplinger H, **Ankerst DP**, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P. Afamin and Apolipoprotein A-IV: Novel protein markers for ovarian cancer. <u>Cancer Epidemiology Biomarkers and Prevention</u> 18(4):1127-33, 2009.

67. **Ankerst DP,** Miyamoto R, Nair PV, Pollock BH, Thompson IM, Parekh DJ. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. <u>Journal of Urology</u> 181(5): 2071-5, 2009.

68. Brawley OW, **Ankerst DP**, Thompson IM. Screening for prostate cancer. <u>CA: A cancer journal for clinicians</u> 59(4):264-73, 2009.

69. Eyre SJ, **Ankerst DP**, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. <u>Journal of Urology</u> 182(6):2653-8, 2009.

70. **Ankerst DP**, Diepolder H, Horster S. Topical treatment of anogenital human papillomavirus infection in male patients. <u>Future Virology</u> 4(6):531-541, 2009.

71. Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, **Ankerst D**, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schroeder FH, Lilja H. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <u>Clinical Cancer Research</u> 16(17): 4374-81, 2010.

72. Liang Y, **Ankerst DP**, Sanchez M, Leach RJ, Thompson IM. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. <u>Urology</u>, 76(5):1268.e1-6, 2010.

73. Horster S, Laubender RP, Lehmeyer L, **Ankerst DP**, Eberle J, Reinert R, Imoehl M, van

der Linden M, Schweiger B, Bogner JR. Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals. Journal of Infection 61(6): 484-91, 2010.

74. Liang Y, **Ankerst DP**, Ketchum NS, Ercole B, Shah G, Shaughnessy, Jr. JD, Leach RJ, Thompson IM. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. Journal of Urology 185(1): 104-10, 2011.

75. Li Y, Haseneyer G, Schoen CC, **Ankerst DP**, Korzun V, Wilde P, Bauer E. High levels of nucleotide diversity and fast decline of linkage disequilibrium in rye (Secale cereale L.) genes involved in frost response. BMC Plant Biology, 11(1):6 (14 pages), 2011.

76. **Ankerst DP**, Pollock BH, Liang Y, Dizdarevic N, Kyrylenko S, Boeck A, Thompson IM, Leach R. Trends and co-trends of prostate-specific antigen and body mass index in a screened population. Urology 78(1):10-16, 2011.

77. Giessen C, Stintzing S, Laubender RP, **Ankerst DP**, Schulz C, Moosmann N, Modest DP, Schalhorn A, Fischer von Weikersthal L, Heinemann V. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. Clinical Colorectal Cancer 10(4):317-24, 2011.

78. Li Y, Boeck A, Haseneyer G, Korzun V, Wilde P, Schoen C-C, **Ankerst DP**, Bauer E. Association analysis of frost tolerance in rye using candidate genes and phenotypic data from controlled, semi-controlled, and field phenotyping platforms. BMC Plant Biology 11: 146 forward, 2011.

79. Williams SB, Salami S, Regan MM, **Ankerst DP**, Wei JT, Rubin MA, Thompson IM, Sanda MG. Selective detection of histologically-aggressive prostate cancer: an early detection research network prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial (PCPT). Cancer 118(10):2651-8, 2012.

80. **Ankerst DP**, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. Biometrical Journal 54(1):127-42, 2012.

81. **Ankerst DP**, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schroeder FH, Lilja H, Vickers AJ. Evaluating the PCPT Risk Calculator in ten international biopsy cohorts: results from the prostate biopsy collaborative group. World Journal of Urology 30(2): 181-7, 2012.

82. Roobol MJ, Schroeder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, **Ankerst DP**, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW. Importance of prostate volume in the European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculators: Results from the Prostate Biopsy Collaborative Group. World Journal of Urology 30(2): 149-55, 2012.

83. Schleip C, **Ankerst DP**, Boeck A, Estrella N, Menzel A. Comprehensive methodological analysis of long-term changes in phenological extremes in Germany. Global Change Biology 18(7): 2349-64, 2012.

84. Hilton WM, Padalecki SS, **Ankerst DP**, Leach RJ, Thompson IM, Jr. Temporal changes in the clinical approach to diagnosing prostate cancer. Journal of the National Cancer Institute Monographs 45: 162-8, 2012.

85. Ziello C, Boeck A, Estrella N, **Ankerst D**, Menzel A. First flowering of wind-pollinated species with the greatest phenological advances in Europe. Ecography 35(11): 1017-23, 2012.

86. Liang Y, **Ankerst DP**, Feng Z, Fu R, Stanford JL, Thompson IM. The risk of biopsy-detectable prostate cancer using the Prostate Cancer Prevention Trial Risk Calculator in a community setting. Urologic Oncology 31(8): 1464-69, 2013.

87. Taylor JM, Park Y, **Ankerst DP**, Proust-Lima C, Williams S, Kestin L, Bae K, Pickles T, Sandler H. Real-time individual predictions of prostate cancer recurrence using joint models. Biometrics 69(1): 206-13, 2013.

88. Giessen C, Laubender RP, **Ankerst DP**, Stintzing S, Modest DP, Mansmann U, Heinemann V. Progression-free survival as a surrogate endpoint for median overall survival in mCRC: Literature-based analysis from 50 randomized first-line trials. Clinical Cancer Research 19(1): 225-35, 2013.

89. **Ankerst DP**, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM. The impact of prostate volume, number of biopsy cores, and AUA symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial Risk Calculator. Journal of Urology 190(1): 70-6, 2013.

90. Hemminki K, **Ankerst DP**, Sundquist J, Mousavi SM. Prostate cancer incidence and survival in immigrants to Sweden. World Journal of Urology 31(6): 1483-8, 2013.

91. Jochner S, Hoefler J, Beck I, Goettlein A, **Ankerst DP**, Traidl-Hoffmann C, Menzel A. Nutrient status – a missing factor in phenological and pollen research. Journal of Experimental Botany 64(7): 2081-92, 2013.

92. Vickers AJ, Sjoberg DD, **Ankerst DP**, Tangen CM, Goodman PJ, Thompson IM, Jr. The Prostate Cancer Prevention Trial Risk Calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer 119(16): 3007-11, 2013.

93. **Ankerst DP**, Till C, Boeck A, Goodman PJ, Tangen CM, Thompson IM. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and AUA symptom score. Urology 82(5): 1076-82, 2013.

94. Boeck A, Dieler J, Biber P, Pretzsch H, **Ankerst DP**. Predicting tree mortality for European beech in southern Germany using spatially-explicit competition indices. Forest Science 60(4): 613-22, 2014.

95. Medina EA, Shi X, Grayson MH, **Ankerst DP**, Livi C, Medina MV, Thompson IM, Leach RJ. The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. Cancer Epidemiology Biomarkers Prevention 23(2): 309-15, 2014.

96. Laube J, Sparks TH, Estrella N, Hoefler J, **Ankerst DP**, Menzel A. Chilling outweighs photoperiod in preventing precocious spring development. Global Change Biology 20(1): 170-82, 2014.

97. **Ankerst DP**, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schroeder FH, Lilja H, Vickers AJ, Thompson IM. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology 32(1): 185-91, 2014.

98. **Ankerst DP**, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM. The Prostate Cancer Prevention Trial Risk Calculator 2.0 for the prediction of low- versus high-grade prostate cancer. Urology 83(6): 1362-7, 2014, Reply in 83(6):1368, 2014.

99. Acevedo-Cabra R, Wiersma Y, **Ankerst D**, Knoke T. Assessment of wildfire hazards with a semi-parametric spatial approach: A case study of wildfires in South America. Environmental Modeling & Assessment 19:533-56, 2014.

100. Giessen C, Laubender RP, **Ankerst DP**, Stintzing S, Modest DP, Schulz C, Mansmann U, Heinemann V. Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomized trials. Acta Oncologica July 14: 1-7, 2014.

101. Thompson IM, Leach RJ, **Ankerst DP**. Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. Journal of the American Medical Association, 312 (10): 995-6, 2014.

102. Grill S, Fallah M, Leach RJ, Thompson IM, Freedland S, Hemminki K, **Ankerst DP**. Incorporation of detailed family history from the Swedish-Family Cancer Database into the Prostate Cancer Prevention Trial Risk Calculator. Journal of Urology 193(2): 460-5, 2015.

103. Winter S, Hoefler J, Michel AK, Boeck A, **Ankerst DP**. Association of tree and plot characteristics with microhabitat formation in European beech and Douglas-fir forests. European Journal of Forest Research 134: 335-347, 2015.

104. Nieboer D, Vergouwe Y, Roobol MJ, **Ankerst DP**, Kattan MW, Vickers AJ, Steyerberg EW, the Prostate Biopsy Collaborative Group. Non-linear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative group. Journal of Clinical Epidemiology 68(4): 426-34, 2015.

105. Grill S, Fallah M, Leach RJ, Thompson IM, Hemminki K, **Ankerst DP**. A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation. Journal of Clinical Epidemiology 68(5):563-73, 2015.

106. Strobl A, Thompson IM, Vickers A, **Ankerst DP**. The next generation of clinical decision-making tools: development of a real-time prediction tool for outcome of prostate biopsy in response to a continuously evolving prostate cancer landscape. Journal of Urology 194(1):58-64, 2015.

107. Gelfond J, Choate K, **Ankerst DP**, Hernandez J, Leach RJ, Thompson IM, Jr. Intermediate-term risk of prostate cancer is directly related to baseline PSA: implications for reducing the burden of PSA screening. Journal of Urology 194(1):46-51, 2015.

108. Strobl AN, Vickers AJ, van Calster B, Steyerberg E, Leach RJ, Thompson IM, **Ankerst DP**. Improving patient prostate cancer risk assessment: moving from static, globally-applied to dynamic, practice-specific cancer risk calculators. Journal of Biomedical Informatics 56:87-93, 2015.

109. **Ankerst DP**, Xia J, Thompson IM, Jr., Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision medicine in active surveillance for prostate cancer: development of the Canary-EDRN active surveillance biopsy risk calculator. European Urology 68(6):1083-8, 2015.

110. Kuehn AR, Grill S, Baumgarten M, **Ankerst DP**, Matyssek R. Daily growth of European beech (Fagus sylvatica L.) on moist sites is affected by short-term drought rather than ozone uptake. Trees 29(5): 1501-19, 2015.

111. **Ankerst DP**, Liss M, Zapata D, Hoefler J, Thompson IM, Leach RJ. A case control study of sarcosine as an early prostate cancer biomarker. BMC Urology 15(1):99, 2015.

112. Liss MA, **Ankerst D**, Zapata D, Hernandez J, Leach RJ, Thompson IM. Prevalence of isolated "pre-malignant" lesions on prostate biopsy in a racially diverse community screened cohort. Open Journal of Urology 5(12): DOI: 10.4236/oju.2015.512034, 2015.

113. Brath JMS, Grill S, **Ankerst DP**, Thompson, IM, Jr., Gschwend JE, Herkommer K. No

detrimental effect of a positive family history on long-term outcomes following radical prostatectomy. Journal of Urology 195(2): 343-8, 2016.

114. Matiu M, **Ankerst DP**, Menzel A. Asymmetric trends in seasonal temperature variability in instrumental records from ten stations in Switzerland, Germany and the UK from 1864 to 2012. International Journal of Climatology 36(1): 13-27, 2016.

115. Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, **Ankerst DP**, Liss MA. Finasteride reduces risk of bladder cancer in large, prospective screening study. European Urology 69(3): 407-10, 2016.

116. **Ankerst DP**, Gelfond J, Goros M, Herrera J, Strobl A, Thompson IM, Jr., Hernandez J, Leach RJ. Serial percent-free PSA in combination with PSA for population-based early detection of prostate cancer. Journal of Urology 196(2): 355-360, 2016.

117. Chen H, Liu X, Brendler CB, **Ankerst DP**, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate 76(12): 1120 -29, 2016.

118. Reim D, Strobl AN, Buchner C, Schirren R, Mueller W, Luppa P, **Ankerst DP**, Friess H, Novotny A. Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome: A retrospective propensity score weighted analysis on 610 curatively resected gastric cancer patients. Medicine 95(29): e4322, 2016.

119. Patel TA, Puppala M, Ogunti R, Ensor JE, He TC, Shewale JB, **Ankerst DP**, Kaklamani VG, Rodriguez AA, Wong STC, Chang JC. Correlating mammographic and pathological findings in clinical decision support using natural language processing and data mining methods. Cancer 123(1): 114-21, 2017.

120. Adam J, Brandmaier S, Leonhardt J, Scheerer MF, Mohney RP, Xu T, Bi J, Rotter M, Troll M, Chi S, Heier M, Herder C, Rathmann W, Giani G, Adamski J, Illig T, Strauch K, Li Y, Gieger C, Peters A, Suhre K, **Ankerst D**, Meitinger T, de Angelis MH, Roden M, Neschen S, Kastenmueller G, Wang-Sattler R. Metformin effect on non-targeted metabolite profiles in patients with type 2 diabetes and multiple murine tissues. Diabetes 65(12): 3776-3785, 2016, response in 66(5): e3-e4, 2017.

121. Nieboer D, Vergouwe Y, **Ankerst D**, Roobol MJ, Steyerberg EW. Improving prediction models with new markers: a comparison of updating strategies. BMC Medical Research Methodology 16(1):128 – 10 pages, 2016.

122. Chen R, Sjoberg DD, Huang Y, Xie L, Zhou L, He D, Vickers AJ, Sun Y, Chinese Prostate Cancer Consortium, Prostate Biopsy Collaborative Group (including **Ankerst DP**). Prostate specific antigen and prostate cancer in chinese men undergoing initial prostate biopsies compared with western cohorts: data from the PBCG and CPCC. Journal of Urology 197(1): 90-6, 2017.

123. Guinney J, Wang T, Laajala, et al, Prostate Cancer Dream Community (including **Ankerst DP**). Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncology 18(1):132-42, 2017.

124. Grill S, **Ankerst DP**, Gail MH, Chatterjee N, Pfeiffer RM. Comparison of approaches for incorporating new information into existing risk prediction models. Statistics in Medicine 36(7): 1134-56, 2017.

125. Kondofersky I, Laimighofer M, Kurz C, Krautenbacher N, Soellner JF, Dargatz P, Scherb H,

Ankerst DP, Fuchs C. Three general concepts to improve risk prediction: good data, wisdom of the crowd, recalibration. F1000Research 5:2671, 2017.

126. Sadim M, Xu Y, Selig K, Paulus J, Uthe R, Agarwal S, Dubin I, Zaichenko L, McCandlish SA, van Horn L, Mantzoros C, **Ankerst DP**, Kaklamani V. Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Cancer 123(13): 2413-21, 2017.

127. Beyerlein A, Strobl AN, Winkler C, Carpus M, Knopff A, Donnachie E, **Ankerst DP**, Ziegler A-G. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine 35(14): 1735-41, 2017.

128. Matiu M, **Ankerst DP**, Menzel A. Interactions between temperature and drought in global and regional crop yield variability during 1961 – 2014. PLOS One 12(5): e0178339, 2017.

129. Seyednasrollah F, Koestler DC, Wang T, Prostate Cancer Dream Community (including **Ankerst DP**), et al. A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer. JCO Clinical Cancer Informatics 1: 1-15, 2017.

130. Kolo H, **Ankerst D**, Knoke T. Predicting natural forest regeneration: a statistical model based on inventory data. European Journal of Forest Research 136(5-6): 923-38, 2017.

131. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, **Ankerst D**, Gulati R, Carter B, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative analysis of biopsy upgrading in four prostate cancer active surveillance cohorts. Annals of Internal Medicine 168(1): 1-9, 2018.

132. Thalgott M, Kron M, Brath JM, **Ankerst DP**, Thompson IM, Gschwend JE, Herkommer K. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy. World Journal of Urology 36(2): 177-85, 2018.

133. **Ankerst DP**, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA. Incorporation of urinary PCA3 and T2:ERG into the Prostate Cancer Prevention Trial Risk Calculator, EU Focus, to appear, 2018.

134. **Ankerst DP**, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. European Urology 74(2):197-203, 2018.

135. Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Rourke E, Basler J, **Ankerst D**, Shah DP. Metabolic biosynthesis pathways identified from fecal microbiome associated prostate cancer. European Urology, 2018, to appear.

BOOK CHAPTERS, REVIEWS, EDITORIALS

136. **Pauler DK**. Discussion of "Quantifying Surprise in the Data and Model Verification'' by MJ Bayarri and JO Berger. In *Bayesian Statistics 6*, eds. Bernardo JM, Berger JO, Dawid AP and Smith AFM. Oxford: Clarendon Press pp.70-72, 1999.

137. **Pauler DK**, Wakefield JC. Modeling and Implementation Issues in Bayesian Meta-Analysis. In *Bayesian Meta-Analysis*. eds. Stangl D and Berry D. New York: Marcel-Dekker, Inc. pp.205-230, 2000.

138. **Pauler DK**, Hardin J, Faulkner J, Leblanc M, Crowley JJ. Survival Analysis with Gene Expression Arrays. In *Handbook of Statistics Vol. 23*, eds. CR Rao and

Balakrishnan, Elsevier North Holland: Amsterdam, pp. 675—688, 2004.

139. **Pauler DK**. Bayes Factors. In *Encyclopedia of Biostatistics*, 2nd Edition, Volume 1, eds. P. Armitage and T. Colton, John Wiley & Sons, pp. 301—303, 2005.

140. **Ankerst DP**. Review of *Kendall's Advanced Theory of Statistics, Vol 2B: Bayesian Inference (2nd ed.)* by A. O'Hagan and J. Forster. Journal of the American Statistical Association, Book Reviews, 1465-1466, 2005.

141. **Ankerst DP**, Finkelstein DM. Clinical monitoring based on joint models for longitudinal biomarkers and event times, In *Handbook of statistics in clinical oncology, 2nd edition*, JC Crowley and DP Ankerst (eds) Boca Raton: Chapman & Hall/CRC Taylor & Francis Group, pp. 397-418, 2006.

142. Hsu L, Faulkner JR, Grove D, **Ankerst DP.** Some practical considerations for analysis of spotted microarray data, In *Handbook of statistics in clinical oncology, 2nd edition*, JC Crowley and DP Ankerst (eds) Boca Raton: Chapman & Hall/CRC Taylor & Francis Group, pp. 383-394, 2006.

143. **Ankerst DP**, Thompson IM. Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers. Journal of Urology 177: 426-427, 2007.

144. Etzioni RD, **Ankerst DP**, Thompson IM. Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. Journal of the National Cancer Institute 99(6): 489-90, 2007.

145. Parekh DJ, **Ankerst DP**, Thompson IM. Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. Journal of the National Cancer Institute 99: 496-497, 2007.

146. Thompson IM, **Ankerst DP**. The performance characteristics of prostate-specific antigen for prostate cancer screening. In *Prostate cancer screening, 2nd ed*, IM Thompson, DP Ankerst, CM Tangen (eds). Humana Press, pp. 61-70, 2009.

147. **Ankerst DP**, Thompson IM. Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator. In *Prostate cancer screening, 2nd ed*, IM Thompson, DP Ankerst, CM Tangen (eds). Humana Press, pp. 195-203, 2009.

148. Zheng Y, **Ankerst DP**. Statistical evaluation of markers and risk tools for prostate cancer classification and prediction. In *Prostate cancer screening, 2nd ed*, IM Thompson, DP Ankerst, CM Tangen (eds). Humana Press, pp. 307-318, 2009.

149. **Ankerst DP**. Pitfalls in prostate cancer biomarker evaluation studies. In *Prostate cancer screening, 2nd ed*, IM Thompson, DP Ankerst, CM Tangen (eds). Humana Press, pp. 319-329, 2009.

150. Thompson IM, **Ankerst DP**, Tangen CM. Prostate-specific antigen, risk factors and prostate cancer: Confounders nestled in an enigma. Journal of the National Cancer Institute 102(17): 1299-301, 2010.

151. Thompson IM, Jr, Leach RJ, **Ankerst DP**. Prostate cancer detection: a view of the future. European Urology 59(2): 191-193, 2011.

152. **Ankerst DP**, Liang Y. Risk Calculators, In *Handbook of statistics in clinical oncology,3rd edition*, JC Crowley and A Hoering (eds) Boca Raton: Taylor & Francis Group, pp. 529-554, 2012.

153. Thompson IM, **Ankerst DP.** The benefits of risk assessment tools for prostate cancer. European Urology 61(4): 662-3, 2012.

154. Thompson IM, **Ankerst DP**. Commentary to "Management of a patient with a persistently elevated PSA and negative biopsy" by JC Presti, Jr. AUA Update Series 31,

Lesson 1, 6-7, 2012.

155. Thompson IM, **Ankerst DP**. Editorial for special issue on epidemiology and prevention of prostate cancer. World Journal of Urology 30(2):129-30, 2012.

156. **Ankerst DP,** Thompson IM. Re: Combining 33 genetic variants with prostate-specific antigen for the prediction of prostate cancer: longitudinal study. European Urology 62(1): 180, 2012.

157. Biber P, Huber C, **Ankerst D**, Weis W. Reaktion von Konkurrenzmodus und Zuwachs auf Kalkung und Beregnung. DVFFA-Sektion Ertragskunde, pp. 41 – 52, 2012.

158. **Ankerst DP**, Seifert-Klauss V, Kiechle M. Translational Risk Models. In Risk: A Multi-disciplinary Introduction, eds. C Klueppelberg, D Straub, IM Welpe, Springer, Heidelberg, pp. 441-58, 2014.

159. Thompson IM, **Ankerst DP.** The role of magnetic resonance imaging in prostate cancer: focusing on what really matters. European Urology 70(4): 574-75, 2016.

160. **Ankerst DP**. Review of *Methodological Developments in Data Linkage* by K Harron, H Goldstein and C Dibben, eds, Biometrics 72: 661-62, 2016.

161. **Ankerst DP**. Review of *Applied Longitudinal Analysis* by GM Fitzmaurice, NM Laird and JH Ware, Biometrics 72: 1009, 2016.

162. **Ankerst DP**. Referee Report For: Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients. F1000Research 5:2676, 2016.

163. **Ankerst DP**. Review of *Applied Multivariate Analysis with R* by D Zelterman, Biometrics 73:358-9, 2017.

164. Pruthi DK, **Ankerst DP**, Liss MA. Novel definitions of low-risk and high-risk prostate cancer: implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool, European Urology 72(1):52-53, 2017.

165. **Ankerst DP**, Strobl A, Grill S. Statistical methodology and engineering for next generation clinical risk calculators. In *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. S Matsui, J Crowley (eds) Heidelberg: Springer, pp. 275-295, 2017.

166. **Ankerst DP,** Review of *Data and Safety Monitoring Committees in Clinical Trials, 2nd ed* by J Herson, Biometrics 74:771, 2018.

EDITORSHIPS

167. Gatsonis C, Carriquiry A, Gelman A, Higdon D, Kass RE, **Pauler DK**, Verdinelli I (eds). *Case Studies in Bayesian Statistics Vol. VI. Lecture Notes in Statistics 167*. New York: Springer, 2002.

168. Crowley JC, **Ankerst DP** (eds). *Handbook of statistics in clinical oncology, 2nd edition*, Boca Raton: Chapman & Hall/CRC Taylor & Francis Group, 2006.

169. **Ankerst DP**, Tangen CM, Thompson IM (eds). *Prostate cancer screening, 2nd edition*, Humana Press, 2009.

170. **Ankerst DP**. Associate editor Bayesian Analysis, 2002 – 2005.

171. **Ankerst DP**. Associate editor Biometrical Journal, 2010 – 2012.

172. **Ankerst DP**. Associate editor Journal of the American Statistical Association Case Studies and Applications, 2006 – 2012.

173. Thompson IM, **Ankerst DP** (guest eds). Special issue on Prostate Cancer: Epidemiology and Prevention, World Journal of Urology 30(2), 2012.

174. **Ankerst DP**, Editor Biometrics Book Reviews, 2016 – 2018.